 |
C-Peptide from
Prepro-Insulin-like Peptide
|
|
| The INSL3-LGR8/GREAT ligand-receptor
pair in human cryptorchidism |
| Testicular descent is
a complex multistep embryonic process requiring the interaction
between anatomical and hormonal factors. Failure in any of these
steps results in cryptorchidism, the most frequent congenital anomaly
of the urogenital tract in human males. Evidence for a genetic cause
for cryptorchidism is numerous and supported by animal models. In
particular, INSL3 and LGR8/GREAT proteins seem to act as ligand
and receptor, respectively, and to have a role in gubernaculum development
involved in testicular descent. In a cohort of 87 ex-cryptorchid
patients and 80 controls, we looked for mutations in INSL3 and LGR8/GREAT
genes by sequencing. Patients were classified on the basis of seminal,
hormonal, and testicular cytological analyses. We found three mutations
in the INSL3 gene in four patients and one LGR8/GREAT mutation in
four patients (8 of 87, 9.2%). The eight patients show different
phenotypes, ranging from normozoospermia to complete azoospermia,
and from bilateral cryptorchidism to retractile testes. Furthermore,
the endocrine function of the testis appears normal in all subjects.
The findings of our study demonstrate that INSL3-LGR8/GREAT mutations
are frequently associated with human cryptorchidism and are maternally
inherited. The only clinical consequence of alterations of the INSL3-LGR8/GREAT
system seems to be failure of the testis to normally descend in
the scrotum during embryonic development, without affecting the
spermatogenic and endocrine components of the testis itself. |
| Ferlin A, et al. J Clin Endocrinol Metab.
2003 Sep;88(9):4273-9 |
|
Insulin-like 3/relaxin-like factor gene
mutations are associated with cryptorchidism |
| Cryptorchidism is a common anomaly of male
sexual differentiation. Two phases of testicular descent are recognized,
transabdominal and inguinoscrotal. With evidence that androgens and
Mullerian inhibitory hormone were not completely responsible for testicular
descent, the existence of a third testicular hormone mediating testicular
descent was postulated. Insulin-like 3 (INSL3) [also known as relaxin-like
factor (RLF) and Leydig insulin-like protein (LEY I-L)] is a member
of the insulin/relaxin hormone superfamily that is highly expressed
in Leydig cells. The phenotype of transgenic mice with targeted deletion
of the Insl3 gene was bilateral cryptorchidism with morphological
evidence of abnormal gubernacular development. With this implicit
evidence that Insl3 mediates testicular descent in mice, we performed
mutation detection analysis of the coding regions of the 2 exon INSL3
gene in genomic DNA samples obtained from 145 formerly cryptorchid
patients and 36 adult male controls. Single-strand conformational
polymorphism analysis was used for the mutation detection studies.
Two mutations, R49X and P69L, and several polymorphisms were identified.
Both mutations were located in the connecting peptide region of the
protein. The frequency of INSL3/RLF gene mutations as a cause of cryptorchidism
is low, because only 2 of 145 (1.4%) formerly cryptorchid patients
were found to have mutations. |
| Tomboc M, et al. J Clin Endocrinol Metab.
2000 Nov;85(11):4013-8 |
|
A novel mutation of the insulin-like
3 gene in patients with cryptorchidism |
| Two independent studies demonstrated that
transgenic mice with a targeted deletion of the insulin-like 3 ( INSL3)
gene presented bilateral cryptorchidism. Studies in humans have investigated
the possibility that mutations in the INSL3 gene are the cause of
cryptorchidism. In the present study, genomic DNA was obtained from
150 patients with idiopathic cryptorchidism. DNA was amplified and
the polymerase chain reaction products of both exons were sequenced.
A previously unidentified missense mutation was found in only one
of the patients studied. In exon 2, a heterozygous C/G substitution
at nucleotide 2560, which turned asparagine into lysine at codon 86,
was documented. The familial study revealed that the mother was a
heterozygous carrier of the mutation and the father was a homozygote
wild type. We also found three polymorphic changes, previously reported
in exon 1. The Asn-into-Lys change is likely deleterious because it
leads to a nonconservative amino acid substitution, changing a highly
conserved residue. This mutation, located in the A-chain of the INSL3
protein, is the first mutation reported in this region. This finding
provides new evidence that INSL3 is involved in testicular descent
in humans; however, mutations of this gene are not a frequent cause
of cryptorchidism. |
| Canto P, et al. J Hum Genet. 2003;48(2):86-90 |
|
Using SSCP analysis, we have identified
three variants involving the coding region and one involving
the intron in the INSL3/RLF gene. The 2450C T
mutation that changes codon 49 from arginine to a termination
codon is clearly a deleterious mutation because it leads to
a truncated protein product lacking the A chain. The 2511
C T
change that changes codon 69 from proline to leucine is
likely deleterious because it leads to a nonconservative
amino acid change, changes a highly conserved residue,
and occurs in less than 1% of the population (Fig. 5 ).
Both mutations occur in the connecting peptide region of the
INSL3/RLF protein. The intron variant seems to be a rare polymorphism
occurring preferentially in African-Americans. The linked
L18L;A36T variant seems to be a common polymorphism because
the frequency of the less common allele is high and is
similar among the patients and control subjects (32.8% and 29.2%,
respectively). Tomboc M, et al. J Clin Endocrinol Metab. 2000
Nov;85(11):4013-8 |
| 
|
| Comparison of protein sequences. Amino
acid residues are indicated by the single universal letter code.
The R residue at codon 49 and the P residue at position 69 are underlined.
Tomboc M, et al. J Clin Endocrinol Metab. 2000 Nov;85(11):4013-8 |
| 
|
|
Restriction fragment length polymorphism analysis. Upper
portion, Diagram of family pedigree; lower portion,
results of BsmaI digest. The 2450C T
variant causes the loss of a BsmaI site. Carrier status is
indicated by the shaded markers in the pedigree diagram.
Tomboc M, et al. J Clin Endocrinol Metab. 2000 Nov;85(11):4013-8
|
|
|
|

|
|
| |
|
|
|
|
|
|
|
|
|
|

|
|
|
|
|
|
|
|
| |
| Catalog No. |
Product Name |
Quantity |
$US/ |
Euro |
| H-035-48 |
INSL3,
C Peptide (Human) Antiserum |
100ml |
$450 |
428 |
| G-035-48 |
INSL3, C Peptide (Human)
Purified IgG |
200mg |
$450 |
428 |
| B-G-035-48 |
INSL3, C Peptide (Human)
Purified IgG, Biotin Labeled |
100ml |
$450 |
428 |
| FG-G-035-48A |
INSL3, C Peptide (Human)
Purified IgG, FAM Labeled |
100ml |
$450 |
428 |
| FG-G-035-48B |
INSL3, C Peptide (Human)
Purified IgG, FITC Labeled |
100ml |
$450 |
428 |
| FR-G-035-48 |
INSL3, C Peptide (Human)
Purified IgG, Rhodamine Labeled |
100ml |
$450 |
428 |
| FC3-G-035-48 |
INSL3, C Peptide (Human)
Purified IgG, Cy3 Labeled |
100ml |
$550 |
523 |
| H-035-52 |
INSL7,
C Peptide (Human) Antiserum for Immunohistochemistry |
100ml |
$450 |
428 |
| G-035-52 |
INSL7,
C Peptide (Human) Purified IgG |
200mg |
$450 |
428 |
| B-G-035-52 |
INSL7,
C Peptide (Human), Purified IgG, Biotin Labeled |
100ml |
$495 |
470 |
| FC3-G-035-52 |
INSL7,
C Peptide (Human), Purified IgG, Cy3 Labeled |
100ml |
$595 |
565 |
| FC5-G-035-52 |
INSL7,
C Peptide (Human), Purified IgG, Cy5 Labeled |
100ml |
$595 |
565 |
| FG-G-035-52-A |
INSL7,
C Peptide (Human), Purified IgG, FAM Labeled |
100ml |
$495 |
470 |
| FG-G-035-52-B |
INSL7,
C Peptide (Human), Purified IgG, FITC Labeled |
100ml |
$495 |
470 |
| FR-G-035-52 |
INSL7,
C Peptide (Human), Purified IgG, Rhodamine Labeled |
100ml |
$525 |
499 |
| RK-035-52 |
INSL7,
C Peptide (Human) RIA Kit |
125
Tubes |
$475 |
451 |
Found 23 products for INSL AND C
Peptide. Showing from 1 to 23 in
alphabetical order.
| 035-47 |
INSL
3 C Peptide / INSL 3 Prepro (51-94) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (51-94) (Mouse) |
100 µg |
$250 |
238 |
| H-035-47 |
INSL
3 C Peptide / INSL 3 Prepro (51-94) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (51-94) (Mouse)
- Antiserum for Immunohistochemistry |
50 µl |
$450 |
428 |
| B-035-47 |
INSL
3 C Peptide / INSL 3 Prepro (51-94) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (51-94) (Mouse)
- Biotin Labeled |
20 µg |
$350 |
333 |
| FC3-035-47 |
INSL
3 C Peptide / INSL 3 Prepro (51-94) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (51-94) (Mouse)
- CY3 Labeled |
1
nmol |
$500 |
475 |
| FG-035-47-A |
INSL
3 C Peptide / INSL 3 Prepro (51-94) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (51-94) (Mouse)
- FAM Labeled |
1
nmole |
$350 |
333 |
| B-G-035-47 |
INSL
3 C Peptide / INSL 3 Prepro (51-94) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (51-94) (Mouse)
- Purified IgG Biotin Labeled |
100 µl |
$450 |
428 |
| FG-G-035-47-A |
INSL
3 C Peptide / INSL 3 Prepro (51-94) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (51-94) (Mouse)
- Purified IgG FAM Labeled |
100 µl |
$500 |
475 |
| FR-035-47 |
INSL
3 C Peptide / INSL 3 Prepro (51-94) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (51-94) (Mouse)
- Rhodamine Labeled |
1
nmol |
$350 |
333 |
| 035-48 |
INSL
3 C Peptide / INSL 3 Prepro (58-105) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (58-105) (Human) |
100 µg |
$300 |
285 |
| H-035-48 |
INSL
3 C Peptide / INSL 3 Prepro (58-105) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (58-105) (Human)
- Antiserum for Immunohistochemistry |
50 µl |
$450 |
428 |
| B-035-48 |
INSL
3 C Peptide / INSL 3 Prepro (58-105) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (58-105) (Human)
- Biotin Labeled |
20 µg |
$350 |
333 |
| FC3-035-48 |
INSL
3 C Peptide / INSL 3 Prepro (58-105) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (58-105) (Human)
- CY3 Labeled |
1
nmol |
$500 |
475 |
| FG-035-48-A |
INSL
3 C Peptide / INSL 3 Prepro (58-105) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (58-105) (Human)
- FAM Labeled |
1
nmol |
$350 |
333 |
| T-035-48 |
INSL
3 C Peptide / INSL 3 Prepro (58-105) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (58-105) (Human)
- Iodine 125 Labeled Tracer |
10 µCi |
$550 |
523 |
| T-G-035-48 |
INSL
3 C Peptide / INSL 3 Prepro (58-105) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (58-105) (Human)
- Purified IgG - Iodine 125 Labeled Tracer |
10 µCi |
$550 |
523 |
| FR-035-48 |
INSL
3 C Peptide / INSL 3 Prepro (58-105) / Insulin-like
3 C Peptide / Insulin-like 3 Prepro (58-105) (Human)
- Rhodamine Labeled |
1
nmol |
$350 |
333 |
| 035-01 |
C-Peptide
(Human) |
200 µg |
$75 |
71 |
| RAB-035-01 |
C-Peptide
(Human), Antibody for RIA |
125
RIA Tubes |
$150 |
143 |
| H-035-01 |
C-Peptide
(Human), Antiserum for Immunohistochemistry |
50 µl |
$175 |
166 |
| B-035-01 |
C-Peptide
(Human) - Biotin Labeled |
20 µg |
$300 |
285 |
| FC3-035-01 |
C-Peptide
(Human) - CY3 Labeled |
1
nmol |
$450 |
428 |
| EK-035-01 |
C-Peptide
(Human), EIA Kit |
96
wells |
$350 |
333 |
| FG-035-01-A |
C-Peptide
(Human), FAM Labeled |
1
nmol |
$200 |
190 |
| G-035-01 |
C-Peptide
(Human) - Purified IgG Antibody |
400 µg |
$325 |
309 |
| T-G-035-01 |
C-Peptide
(Human) - Purified IgG - Iodine 125 Labeled Tracer |
10 µCi |
$550 |
523 |
| FR-035-01 |
C-Peptide
(Human) - Rhodamine Labeled |
1
nmol |
$300 |
285 |
| RK-035-01 |
C-Peptide
(Human), RIA Kit |
1
kit |
$475 |
451 |
| 035-58 |
INSL-5
C-Peptide (49-106) [Prepro] (Human) |
100 µg |
$280 |
266 |
| 035-54 |
INSL
6 C-Peptide (153-168) (Human) |
100µg |
$120 |
114 |
| 035-57 |
INSL-6
C-Peptide (55-118) [Prepro] (Human) |
100 µg |
$300 |
285 |
| 035-55 |
INSL
6 Prepro-C-Peptide (121-148) (Human) |
100µg |
$180 |
171 |
|
|
INSL
Related Products |
| |
|
|
|